Dasatinib

Generic Name: Dasatinib

Brand Names: Sprycel

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₆ClN_₇O_₂S

CAS Number: 302962-49-8

Unique Ingredient Identifier: X78UG0A0RN

Background: Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...

Indication: Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

Phase 1

Completed

Conditions: Scleroderma

Interventions: Drug: dasatinib

First Posted Date: 2008-10-02

Last Posted Date: 2012-02-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 47

Registration Number: NCT00764309

Locations: 🇺🇸
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
🇺🇸
Boston University School Of Medicine, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States

and more 10 locations

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Phase 2

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Dasatinib
Drug: Fulvestrant

First Posted Date: 2008-09-17

Last Posted Date: 2016-05-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT00754325

Locations: 🇺🇸
Kansas City Cancer Center, Llc., Overland Park, Kansas, United States
🇺🇸
Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States
🇺🇸
Us Oncology Research, Inc., Houston, Texas, United States

and more 23 locations

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer

Phase 3

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Placebo
Drug: Dasatinib
Drug: Docetaxel
Drug: Prednisone

First Posted Date: 2008-09-01

Last Posted Date: 2016-10-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1930

Registration Number: NCT00744497

Locations: 🇺🇸
Maine Center For Cancer Medicine, Scarborough, Maine, United States
🇺🇸
Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States
🇺🇸
Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States

and more 40 locations

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

First Posted Date: 2008-07-22

Last Posted Date: 2020-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT00720109

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States

and more 131 locations

Solid Tumors Using Ixabepilone and Dasatinib

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: ixabepilone
Drug: Dasatinib

First Posted Date: 2008-07-17

Last Posted Date: 2020-08-05

Lead Sponsor: Medstar Health Research Institute

Target Recruit Count: 19

Registration Number: NCT00717704

Locations: 🇺🇸
Washington Cancer Institute, Washington, District of Columbia, United States

Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

Not Applicable

Completed

Conditions: Transitional Cell Carcinoma of the Bladder

Interventions: Drug: Dasatinib
Procedure: Radical Cystectomy

First Posted Date: 2008-06-27

Last Posted Date: 2016-01-15

Lead Sponsor: Hoosier Cancer Research Network

Target Recruit Count: 25

Registration Number: NCT00706641

Locations: 🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: dasatinib

First Posted Date: 2008-06-19

Last Posted Date: 2023-07-03

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 81

Registration Number: NCT00700882

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States
🇺🇸
Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States

and more 148 locations

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Dasatinib
Drug: Letrozole

First Posted Date: 2008-06-12

Last Posted Date: 2016-06-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 120

Registration Number: NCT00696072

Locations: 🇺🇸
Florida Cancer Institute - New Hope, Hudson, Florida, United States
🇺🇸
Arizona Oncology Associates D.B.A. Hematology Oncology, Tucson, Arizona, United States
🇺🇸
Central Indiana Cancer Centers, Carmel, Indiana, United States

and more 20 locations

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Phase 2

Completed

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Drug: Dasatinib
Other: Laboratory Biomarker Analysis

First Posted Date: 2008-05-05

Last Posted Date: 2016-04-15

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 35

Registration Number: NCT00671788

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Sarasota Memorial Hospital, Sarasota, Florida, United States

and more 17 locations

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: dasatinib
Drug: lapatinib ditosylate
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2008-04-21

Last Posted Date: 2017-03-23

Lead Sponsor: Mayo Clinic

Target Recruit Count: 27

Registration Number: NCT00662636

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy